Experimental pill promises new hope for deadly pancreatic cancer
- On Sunday at the American Society for Clinical Oncology meeting in Chicago, researchers reported that the experimental pill daraxonrasib nearly doubled survival times for patients with advanced pancreatic cancer compared to chemotherapy.
- The drug targets the mutated KRAS gene, found in more than 90 per cent of pancreatic tumours, which continuously signals cancer cells to grow and was long considered 'undruggable' by researchers.
- In the 500-patient trial, daraxonrasib recipients lived a median of 13.2 months versus 6.7 months for chemotherapy patients, with severe side effects in 43.6 per cent of cases compared to 57.5 per cent on chemotherapy.
- Dr. Rachna Shroff of the Arizona Cancer Center called the results 'landscape-changing,' while the Food and Drug Administration plans to expedite review of the drug as a potential new standard of care.
- Researchers are now exploring whether daraxonrasib might shrink tumors to allow for surgery in earlier-stage patients, while the agency currently allows 'expanded access' to the experimental treatment for patients meeting specific criteria.
133 Articles
133 Articles
The results of a phase 3 trial with a new molecule, daroxonrasib, confirm a doubling of overall survival in metastasic patients. ...
Pill can double pancreatic cancer survival time
A breakthrough daily pill has doubled survival times in patients with advanced pancreatic cancer, prompting experts to hail the treatment as a potential revolution against one of the deadliest forms of the disease.
Daily tablet linked to 'unprecedented survival' in world's deadliest cancer
A revolutionary daily tablet has demonstrated the ability to extend survival times twofold for patients suffering from the world's most lethal form of cancer, according to groundbreaking clinical trial findings unveiled at a major international oncology gathering.The medication, known as daraxonrasib, represents what specialists are describing as one of the most significant advances in pancreatic cancer treatment seen in recent decades.Results f…
Coverage Details
Bias Distribution
- 51% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
